ASH 2017 | The practical challenges of using novel CAR T-cell agents
David Maloney, BSc, MD, PhD, of Fred Hutchinson Cancer Research Center, Seattle, WA, gives an overview of the practical challenges of using novel CAR T-cell agents. He explains that many patients may have major complications with cytokine release syndrome or neurotoxicity, which must be treated with specialized treatments, such as tocilizumab. Due to this, these agents are currently being rolled out in a measured fashion to limit and monitor these complications. Recorded at American Society of Hematology 2017 Annual Meeting, held in Atlanta, GA.
Get great new content delivered to your inboxSign up